3/30
04:40 pm
jspr
Jasper Therapeutics GAAP EPS of -$0.32 beats by $0.48 [Seeking Alpha]
Medium
Report
Jasper Therapeutics GAAP EPS of -$0.32 beats by $0.48 [Seeking Alpha]
3/30
04:30 pm
jspr
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Low
Report
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
3/29
05:02 pm
jspr
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab [Yahoo! Finance]
High
Report
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab [Yahoo! Finance]
3/23
08:42 am
jspr
Jasper Therapeutics (JSPR) is now covered by UBS Group AG. They set a "neutral" rating and a $1.50 price target on the stock.
Low
Report
Jasper Therapeutics (JSPR) is now covered by UBS Group AG. They set a "neutral" rating and a $1.50 price target on the stock.
2/24
04:48 pm
jspr
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference [Yahoo! Finance]
Low
Report
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference [Yahoo! Finance]
2/24
04:30 pm
jspr
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Low
Report
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
2/5
10:45 am
jspr
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
Medium
Report
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
1/24
05:09 am
jspr
Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.